SEARCH:   Advanced

Blood, 17 September 2009, Vol. 114, No. 12, pp. 2489-2496. Prepublished online as a Blood First Edition Paper on June 15, 2009; DOI 10.1182/blood-2009-04-215152. This Article Full Text Full Text (PDF) Supplemental Appendices and Tables All Versions of this Article: blood-2009-04-215152v1 114/12/2489    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Balgobind, B. V. Articles by van den Heuvel-Eibrink, M. M. PubMed PubMed Citation Articles by Balgobind, B. V. Articles by van den Heuvel-Eibrink, M. M. Related Collections Free Research Articles Myeloid Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  MYELOID NEOPLASIA Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study Brian V. Balgobind1, Susana C. Raimondi2,3,*, Jochen Harbott4,*, Martin Zimmermann5, Todd A. Alonzo3, Anne Auvrignon6, H. Berna Beverloo7,8, Myron Chang9, Ursula Creutzig10, Michael N. Dworzak11, Erik Forestier12, Brenda Gibson13, Henrik Hasle14, Christine J. Harrison15, Nyla A. Heerema3,16, Gertjan J. L. Kaspers1719, Anna Leszl20, Nathalia Litvinko21, Luca Lo Nigro22, Akira Morimoto23,24, Christine Perot6, Rob Pieters1, Dirk Reinhardt5, Jeffrey E. Rubnitz2, Franklin O. Smith3,25, Jan Stary26, Irina Stasevich21, Sabine Strehl11, Takashi Taga23,27, Daisuke Tomizawa23,28, David Webb18,29, Zuzana Zemanova30, C. Michel Zwaan1,17,, and Marry M. van den Heuvel-Eibrink1,17, 1 Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children's Hospital, Rotterdam, The Netherlands; 2 St Jude Children's Research Hospital, Memphis, TN; 3 Children's Oncology Group, Arcadia, CA; 4 Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Department of Pediatric Hematology and Oncology, University of Giessen, Giessen, Germany; 5 Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany; 6 French Leucémie Aique Myeloide Enfant, Hopital Trousseau, Paris, France; 7 Dutch Childhood Oncology Group, Dutch Working Group on Hemato-Oncologic Genome Diagnostics, The Hague, The Netherlands; 8 Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands; 9 Children's Oncology Group, Data Center, Gainesville, FL; 10 Acute Myeloid Leukemia-Berlin-Frankfurt-Münster Study Group, Pediatric Hematology/Oncology, University Hospital, Munster, Germany; 11 Children's Cancer Research Institute, Vienna, Austria; 12 Nordic Society for Pediatric Hematology and Oncology, Department of Clinical Science, Pediatrics, Umeå University Hospital, Umeå, Sweden; 13 Department of Pediatric Oncology/Hematology, Royal Hospital for Sick Children, Glasgow, United Kingdom; 14 Nordic Society for Pediatric Hematology and Oncology, Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark; 15 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; 16 Department of Pathology, Ohio State University, Columbus; 17 Dutch Childhood Oncology Group, The Hague, The Netherlands; 18 Acute Myeloid Leukemia Committee I-Berlin-Frankfurt-Münster Study Group; 19 Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands; 20 Italian Association of Pediatric Hematology Oncology, Clinica Pediatrica, Università Padova, Padova, Italy; 21 Research Center for Pediatric Oncology and Hematology, Minsk, Belarus; 22 Italian Association of Pediatric Hematology Oncology, Clinica Pediatrica, Università Catania, Catania, Italy; 23 Japanese Pediatric Leukemia/Lymphoma Study Group, Tokyo, Japan; 24 Department of Pediatrics, Jichi Medical University, Tochigi, Japan; 25 Hematology/Oncology and Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, OH; 26 Czech Pediatric Hematology/Oncology, University Hospital Motol and 2nd Medical School, Charles University, Prague, Czech Republic; 27 Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan; 28 Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan; 29 Great Ormond Street Hospital for Children, London, United Kingdom; and 30 Center of Oncocytogenetics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic Translocations involving chromosome 11q23 frequently occur in pediatric acute myeloid leukemia (AML) and are associated with poor prognosis. In most cases, the MLL gene is involved, and more than 50 translocation partners have been described. Clinical outcome data of the 11q23-rearranged subgroups are scarce because most 11q23 series are too small for meaningful analysis of subgroups, although some studies suggest that patients with t(9;11)(p22;q23) have a more favorable prognosis. We retrospectively collected outcome data of 756 children with 11q23- or MLL-rearranged AML from 11 collaborative groups to identify differences in outcome based on translocation partners. All karyotypes were centrally reviewed before assigning patients to subgroups. The event-free survival of 11q23/MLL-rearranged pediatric AML at 5 years from diagnosis was 44% (± 5%), with large differences across subgroups (11% ± 5% to 92% ± 5%). Multivariate analysis identified the following subgroups as independent prognostic predictors: t(1;11)(q21;q23) (hazard ratio [HR] = 0.1, P = .004); t(6;11)(q27;q23) (HR = 2.2, P < .001); t(10;11)(p12;q23) (HR = 1.5, P = .005); and t(10;11)(p11.2;q23) (HR = 2.5, P = .005). We could not confirm the favorable prognosis of the t(9;11)(p22;q23) subgroup. We identified large differences in outcome within 11q23/MLL-rearranged pediatric AML and novel subgroups based on translocation partners that independently predict clinical outcome. Screening for these translocation partners is needed for accurate treatment stratification at diagnosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: T(11q23): brand necessary Beverly J. Lange Blood 2009 114: 2365-2366. [Full Text] [PDF] This article has been cited by other articles: B. J. Lange T(11q23): brand necessary Blood, September 17, 2009; 114(12): 2365 - 2366. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020